The competition for researching and developing new drugs has grown even more intense with each passing year and led to the necessity for larger investments and much longer periods for the completion of product development.

In response to these new domestic, global challenges in R&D, Jeil has been concentrating its focus on limited areas with the potential to create products with competitive advantages over others. In pursuance of this objective, Jeil has set up research laboratories for three sectors, namely, Medicinal chemistry Lab/Pharmacology & Toxicology Lab for the invention of New Molecule Entities (NMEs), an Organic Synthesis laboratory for the development of high valued Active Pharmaceutical Ingredients (APIs), and a Pharmaceutical Technology Research Institute for the development of newly and Incrementally Modified Drugs (IMDs) using existing APIs.